Key result
Structural, pharmacodynamic, and pharmacokinetic differences exist between various ACE inhibitors administered after myocardial infarction, which may lead to differences in clinical outcomes.
Why the study?
Do structural, pharmacodynamic, and pharmacokinetic differences between various ACE inhibitors affect outcomes when administered after myocardial infarction?
Do structural, pharmacodynamic, and pharmacokinetic differences between various ACE inhibitors affect outcomes when administered after myocardial infarction?
This review highlights that structural and pharmacological differences among ACE inhibitors may translate into different clinical outcomes when used after myocardial infarction.
Differences between ACE inhibitors post-MI may affect outcomes; leaves open optimal agent selection pending direct comparisons.
In recent years, growing evidence has suggested a beneficial effect from the use of angiotensin converting enzyme (ACE) inhibitors after myocardial infarction. Since important differences between the structure and effects of the various ACE inhibitors exist, differences in outcome can be expected. This review discusses the structural, pharmacodynamic and pharmacokinetic differences between ACE inhibitors administered after myocardial infarction, both in experimental settings and in clinical practice.
No takes yet. Share an insight, caveat, or question.
Voors et al. (1995) conducted a review in Myocardial infarction. ACE inhibitors was evaluated. Structural, pharmacodynamic, and pharmacokinetic differences exist between various ACE inhibitors administered after myocardial infarction, which may lead to differences in clinical outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: